Mesa Laboratories (MLAB) Earnings Date & Reports

Key Takeaways

• Revenue rose 2.6% year over year to $62.3 million, modestly ahead of Wall Street's consensus estimate.
• Diluted earnings per share (EPS) came in at $0.75, below analyst expectations, while net income climbed 75.3% to $4.3 million.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) increased 21.1% to $17.3 million, lifting the adjusted EBITDA margin to 27.8%.
• Sterilization and Disinfection Control grew roughly 14.6% organically, while Biopharmaceutical Development declined 8.2% on export-control and shipment-timing issues.
• Management issued its first full-year guidance: fiscal 2027 revenue of $250 million to $255 million and adjusted EBITDA of $66 million to $68 million.
• The board authorized a new $40 million share repurchase program, and the company ended the quarter at 1.75x total net leverage.
• For more on Mesa Laboratories, explore its Major News, Today's Price Move, Price Targets, and Forecast pages.
• To discover AI-driven trade ideas and market opportunities, explore Trending AI Robots.

Earnings Context and Why It Matters

Mesa Laboratories, a maker of quality control solutions and life science tools for regulated pharmaceutical, healthcare, and medical device applications, closed its second fiscal quarter ended September 30, 2026 with a distinct shift in narrative. After quarters spent rebuilding delivery reliability and reshaping its portfolio, this report delivered the company's first formal full-year outlook. That milestone matters because it converts management's turnaround rhetoric into measurable targets. Investors are watching closely whether stronger profitability in the core Quality Control businesses can offset softer demand in Biopharmaceutical Development and the deliberate downsizing of Clinical Genomics, a segment now managed for cash generation rather than scale.

Reported Results

For its second fiscal quarter of 2027, Mesa Laboratories reported revenue of $62.3 million, up 2.6% from the prior-year period and slightly above the consensus estimate of roughly $61.6 million. Net income increased 75.3% to $4.3 million, producing diluted EPS of $0.75, which fell short of analyst expectations. Operating income jumped 77.6% to $8.4 million.

Profitability improved meaningfully. Gross margin expanded about 250 basis points (bps) to 64.0%, and adjusted EBITDA grew 21.1% to $17.3 million, representing 27.8% of revenue. By division, Sterilization and Disinfection Control contributed $25.3 million, Calibration Solutions $14.1 million, Biopharmaceutical Development $12.8 million, and Clinical Genomics $10.2 million.

Management also provided fiscal 2027 guidance for the first time, calling for revenue of $250 million to $255 million and adjusted EBITDA of $66 million to $68 million, implying adjusted EBITDA growth of roughly 5% to 8% on revenue growth of approximately 0% to 2%.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters covering industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, and breakout candidates more efficiently than manual screening, supporting more informed decision-making. For investors following names like Mesa Laboratories, it offers a practical way to monitor shifts in momentum and identify new opportunities across the broader market.

Market Reaction and Investor Sentiment

Mesa Laboratories shares closed at $127.82 on November 9, 2026, dipping modestly during the regular session, with additional softness in after-hours trading. The muted-to-negative reaction reflected the headline EPS miss, even as revenue beat estimates and profitability expanded sharply. Investors appeared to weigh the higher-quality earnings growth against lingering concerns in Biopharmaceutical Development, where export-control delays and shipments that slipped past the quarter-end suppressed results, and the ongoing restructuring of Clinical Genomics. The debut of full-year guidance and the new buyback authorization were viewed as positive steps, but the market remained focused on near-term revenue visibility across the faster-growing segments.

Forward Outlook and Key Factors to Monitor

Mesa's first full-year guidance sets a concrete baseline, but the path to hitting it will hinge on several moving parts. Management expects revenue growth to be uneven, with third-quarter revenue roughly flat year over year largely because of lower Clinical Genomics revenue. Excluding Clinical Genomics, the company anticipates continued growth.

The company's savings plan, announced in October, is expected to reduce annualized operating costs by about $9.3 million, with roughly $4.3 million reinvested in commercial capacity and key corporate roles for a net reduction near $5 million. Investors should watch how quickly those savings flow through and whether the reinvestment accelerates growth in Sterilization and Disinfection Control and Calibration Solutions.

Delivery reliability in Sterilization and Disinfection Control remains a focal point. While that business grew in the mid-teens, management cautioned that one key product line tied to past-due backlog is only partially resolved. In Biopharmaceutical Development, the next-generation Gyrolab platform is still targeted for a fiscal 2028 launch, and orders that slipped past the quarter-end are expected to land in the third quarter. Finally, capital allocation will be in the spotlight, as the newly authorized $40 million repurchase program, ongoing debt reduction, and potential small tuck-in acquisitions shape how Mesa deploys its improving cash flow.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations